Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 1017-1021

  Zhu, Jin Hui ^a   Hong, De Fei ^b   Song, Yong Mao ^a   Sun, Li Feng ^a   Wang, Zhi Fei ^b   Wang, Jian Wei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Colorectal cancer; CSE1L; Proliferation

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; GENETICS; HUMAN; M PHASE CELL CYCLE CHECKPOINT; PATHOLOGY; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; COLORECTAL NEOPLASMS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84877660798     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.1017     Document Type: Article

References (21)

1. Akiyama Y, Watkins N, Suzuki H, et al (2003). GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol, 23, 8429.
2. Behrens P, Brinkmann U, Fogt F, Wernert N, Wellmann A (2001). Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development. Anticancer Res, 21, 2413-7.
3. Behrens P, Brinkmann U, Wellmann A (2003). CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis, 8, 39-44.
4. Bera TK, Bera J, Brinkmann U, Tessarollo L, Pastan I (2001). Cse1l is essential for early embryonic growth and development. Mol Cell Biol, 21, 7020-4.
5. Brinkmann U, Brinkmann E, Bera TK, Wellmann A, Pastan I (1999). Tissue-Specific Alternative Splicing of the CSE1L/ CAS (Cellular Apoptosis Susceptibility) Gene* 1. Genomics, 58, 41-9.
6. Castanotto D, Rossi JJ (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457, 426-33.
7. Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S (2011). Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 11, 371.
8. Eberhart CE, Coffey R, Radhika A, et al (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183.
9. Kim JG, Chae YS, Sohn SK, et al (2008). Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res, 14, 62.
10. Liao CF, Luo SF, Shen TY, et al (2008). CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. BMB Rep, 41, 210-6.
11. Liao CF, Luo SF, Li LT, et al (2008). CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Canc Res, 27, 15.
12. Mulkeen AL, Silva T, Yoo PS, et al (2006). Short Interfering RNA-Mediated Gene Silencing of Vascular Endothelial Growth Factor: Effects on Cellular Proliferation in Colon Cancer Cells. Arch Surg, 141, 367-74.
13. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-10.
14. Pai SI, Lin YY, Macaes B, et al (2005). Prospects of RNA interference therapy for cancer. Gene Ther, 13, 464-77.
15. Suzuki H, Watkins DN, Jair KW, et al (2004). Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet, 36, 417-22.
16. Tai CJ, Shen SC, Lee WR, et al (2010). Increased cellular apoptosis susceptibility (CSE1L/CAS) protein expression promotes protrusion extension and enhances migration of MCF-7 breast cancer cells. Exp Cell Res, 316, 2969-81.
17. Tsao TY, Tsai CS, Tung JN, et al (2009a). Function of CSE1L/ CAS in the secretion of HT-29 human colorectal cells and its expression in human colon. Mol Cell Biocheml, 327, 163-70.
18. Tsao TY, Tsai CSS, Tung JN, et al (2009b). Function of CSE1L/ CAS in the secretion of HT-29 human colorectal cells and its expression in human colon. Mol Cell Biocheml, 327, 163-70.
19. Tung MC, Tsai CSS, Tung JN, et al (2009). Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidem Biomar, 18, 1570.
20. Wellmann A, Flemming P, Behrens P, et al (2001). High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. Int J Mol Med, 7, 489.
21. Zhang S, Yang JH, Guo CK, Cai P (2007). Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett, 253, 108-14.